David Marchant PhD

David Marchant, PhD is a Professor in the Department of Medical Microbiology and Immunology at the University of Alberta. He is also a Canada Research Chair in Viral Pathogenesis. He is the founder and CSO of Antibiddies Technologies Inc., which is developing a drug called RespVirex into a preventative antiviral nasal spray that can be easily given to infants and adults. The drugs being developed by his company are derived from his research program at the University of Alberta that studies respiratory viruses like SARS-CoV-2 and Respiratory Syncytial Virus (RSV).